Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 5, 2026Journal of the American Statistical Association

BAP: Bayesian Biomarker-Assisted Platform Design for Dose Ranging in Multi-Agent Multi-Dose Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLi WangYZYujie ZhaoYYYing Yuan

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates a new method for optimizing multiple treatments in one trial, indicating cost savings.

Key Points

  • The aim is to develop a Bayesian platform design that efficiently assesses multiple treatments and doses using biomarkers.
  • Proposed a unified Bayesian design for multi-agent trials with a focus on dose ranging.
  • Incorporated interim monitoring for futility and superiority to optimize treatment allocation.
  • Used simulations to compare the proposed design with conventional designs.
  • The design improved efficiency and reduced costs compared to traditional platform designs.
  • Illustrated through a trial of three agents for systemic lupus erythematosus with favorable response rates at 24 weeks.
  • Showed effective real-time decision-making based on unobserved long-term responses.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a72e7e2226790f37065738ehttps://doi.org/10.1080/01621459.2026.2708370
View Full Paper
Ask AI
Bookmark
Share